US20100178344A1 - Extended-Release Composition Comprising a Somatostatin Derivative in Microparticles - Google Patents

Extended-Release Composition Comprising a Somatostatin Derivative in Microparticles Download PDF

Info

Publication number
US20100178344A1
US20100178344A1 US12/600,740 US60074008A US2010178344A1 US 20100178344 A1 US20100178344 A1 US 20100178344A1 US 60074008 A US60074008 A US 60074008A US 2010178344 A1 US2010178344 A1 US 2010178344A1
Authority
US
United States
Prior art keywords
microparticles
compound
composition according
pharmaceutical composition
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/600,740
Other languages
English (en)
Inventor
Olivier Lambert
Marc Riemenschnitter
Vitomir Vucenovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recordati SA
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38222465&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20100178344(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Assigned to NOVARTIS AG reassignment NOVARTIS AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LAMBERT, OLIVIER, RIEMENSCHNITTER, MARC, VUCENOVIC, VITOMIR
Publication of US20100178344A1 publication Critical patent/US20100178344A1/en
Assigned to RECORDATI AG reassignment RECORDATI AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NOVARTIS AG
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Definitions

  • the present invention relates to improved microparticles comprising a somatostatin analogue, a process of making said microparticles and to pharmaceutical compositions comprising the same.
  • the preferred somatostatin analogue according to the present invention is Compound A of formula
  • Preferred salts for Compound A are the lactate, aspartate, benzoate, succinate and pamoate including mono- and di-salts, more preferably the aspartate di-salt and the pamoate monosalt, most preferred the pamoate monosalt.
  • the compounds of the invention may be prepared in accordance with conventional methods.
  • Compound A and its synthesis have been described in detail e.g. in WO02/10192, the contents of which are incorporated herein by reference.
  • WO05/046645 the contents of which are incorporated herein by reference, describes that administration of microparticles comprising a somatostatin analogue, for instance Compound A, e.g. embedded in a biocompatible pharmacologically acceptable polymer, suspended in a suitable vehicle gives release of all or of substantially all of the active agent over an extended period of time, e.g. several weeks up to 6 months, preferably over at least 4 weeks.
  • a somatostatin analogue for instance Compound A, e.g. embedded in a biocompatible pharmacologically acceptable polymer, suspended in a suitable vehicle gives release of all or of substantially all of the active agent over an extended period of time, e.g. several weeks up to 6 months, preferably over at least 4 weeks.
  • microparticle formulations of Compound A as described in WO05/046645 have sometimes a less favourable pharmakokinetic release profile of the active ingredient (drug).
  • the duration of action sometimes is unsatisfactory, i.e. not long lasting enough.
  • drug burst especially the relatively high initial release of the drug within the first day(s) after administration (drug burst) can lead to problems, such as for instance unwanted side effects including e.g. nausea or temporarily too high blood glucose level.
  • This drug burst is even more concerning at repeated dosing when the plasma concentration of the drug reaches steady state conditions at higher levels.
  • compositions comprising the new microparticels according to the present invention show a lower initial release of the active ingredient and/or a longer duration of action and/or a favourable pharmacokinetic release profile, especially at repeated dosing, compared to pharmaceutical compositions comprising the microparticles described in WO05/046645.
  • compositions according to the present invention can, for instance, be documented by results obtained in clinical studies in humans.
  • FIG. 1 shows comparative release profiles of Compound A in healthy human volunteers following a single dose administration of 40 mg Compound A in microparticles either according to Example 1 or according to Reference example (Example 8 of WO05/046645).
  • the microparticles were suspended in vehicle D and administered intramuscular (i.m.). Blood samples were taken periodically and plasma levels of Compound A were measured by Radioimmunoassay (RIA) analysis.
  • RIA Radioimmunoassay
  • the improved properties of pharmaceutical compositions according to the present invention can, for instance, also be determined by in vivo experiments in rabbits.
  • the results obtained in rabbits can easily and reliably be transferred to the corresponding situation in humans, because the pharmacological profile in rabbits and humans with regard to Compound A are closely related.
  • the release profile of the pharmaceutical compositions according to the present invention after single administration in rabbits can be summarized as follows.
  • the present invention provides a pharmaceutical composition for extended release comprising microparticles with a polymer matrix comprising one or more biodegradable polymers and Compound A pamoate as active ingredient wherein the maximum plasma concentration (burst) of the active ingredient in rabbits within the first 24 hours after administration of 4 mg/kg is below 15, preferably 12 or 10 ng/ml.
  • the pharmaceutical compositions for extended release of the present invention comprises microparticles with a polymer matrix consisting of one or more biodegradable polymers and Compound A pamoate as active ingredient.
  • the present invention provides a pharmaceutical composition for extended release comprising microparticles with a polymer matrix comprising one or more biodegradable polymers and Compound A pamoate as active ingredient wherein in rabbits the ratio of the maximum plasma concentration (burst) of the active ingredient within the first 24 hours after administration and the minimum plasma concentration of the active ingredient between day 2 and 10 after administration is less than 5 or less than 4. Even more preferred is a ratio of the maximum plasma concentration (burst) of the active ingredient within the first 24 hours after administration and the minimum plasma concentration of the active ingredient between day 2 and 10 after administration of less than 3.7 or, preferably, less than 3.6.
  • the present invention provides a pharmaceutical composition for extended release comprising microparticles with a polymer matrix comprising one or more biodegradable polymers and Compound A pamoate as active ingredient wherein in rabbits the maximum plasma concentration (t max ) of Compound A is reached not before day 12 after administration.
  • the present invention provides a pharmaceutical composition for extended release comprising microparticles with a polymer matrix comprising one or more biodegradable polymers and Compound A pamoate as active ingredient wherein in rabbits the plasma concentration of Compound A is above 2 ng/ml between day 2 and day 35 after administration.
  • the present invention provides a pharmaceutical composition for extended release comprising microparticles with a polymer matrix comprising one or more biodegradable polymers and Compound A pamoate as active ingredient wherein the active ingredient Compound A is released over a time period of at least 4 weeks.
  • the present invention provides also a pharmaceutical depot formulation comprising the microparticles of the present invention.
  • the burst release of Compound A can alternatively, or additionally, be measured by an in vitro dissolution test, e.g., as described in Example 4 of the present application.
  • the present invention provides a pharmaceutical composition for extended release comprising microparticles with a polymer matrix comprising one or more biodegradable polymers and Compound A pamoate as active ingredient wherein the burst measured as % of Compound A content after 24 hours is less than 1.2%, less than 1.0%, less than 0.9% or less than 0.8%.
  • the burst measured by the dissolution test as % of Compound A content after 24 hours is conveniently between 0.5% to 1.2% or 0.6% to 1.0%.
  • the present invention provides a method of treatment of a disease amendable to treatment with Compound A in a patient in need of such treatment comprising administering to the patient a dosage form for parenteral administration of Compound A pamoate, said dosage form comprising microparticles as described herein, wherein said dosage form releases Compound A in rabbits such that a maximum plasma concentration (burst) of the active ingredient in rabbits within the first 24 hours after administration of 4 mg/kg is below 15, preferably 12 or 10 ng/ml.
  • the maximum plasma concentration (t max ) of Compound A in rabbits is reached not before day 12 after administration.
  • the plasma concentration of Compound A in rabbits is above 2 ng/ml between day 2 and day 35.
  • the burst release is measured with the method as described in Example 4 and is less than 1.2% or 1% of Compound A content.
  • the administration can for instance be done at least every 2 weeks or at least every 4 weeks (including e.g. monthly) or at least every 6 weeks or at least every 8 weeks (or e.g. every two months).
  • Diseases amenable to Compound A include diseases or disorders with an aetiology comprising or associated with excess GH- and/or IGF-1 secretion.
  • the present invention provides the use of a formulation of compound Compound A obtainable by a process for the preparation of microparticles as described hereinbelow in the manufacture of a medicament for the treatment of disorders with an aetiology comprising or associated with excess GH-secretion and/or excess of IGF-1.
  • the present invention provides the use of Compound A in the manufacture of a medicament for treating a disease amendable to treatment with Compound A wherein Compound A is in a dosage form for parenteral administration comprising microparticles with a polymer matrix comprising one or more biodegradable polymers and Compound A pamoate as active ingredient characterized in that the microparticles release compound A in rabbits is such that a maximum plasma concentration (burst) of the active ingredient in rabbits within the first 24 hours after administration of 4 mg/kg is below 15, preferably 12 or 10 ng/ml. In one embodiment, the maximum plasma concentration (t max ) of Compound A in rabbits is reached not before day 12 after administration.
  • the plasma concentration of Compound A in rabbits is above 2 ng/ml between day 2 and day 35.
  • the burst release may alternatively or additionally be measured by the dissolution test as described in Example 4 and is less than 1.2% or 1% of Compound A content.
  • the present invention provides the use of a pharmaceutical composition for extended release comprising microparticles with a polymer matrix comprising of one or more biodegradable polymers, e.g. a mixture of a linear polylactide-co-glycolide polymer and a branched polylactide-co-glycolide polymer, and Compound A pamoate as active ingredient, wherein the microparticles have been prepared by a process for preparing microparticles as described hereinbelow characterized in that methylene chloride in a concentration from 14.24% to 17.45%, preferably from 15.0% to 16.5%, even more preferred about 15.9% (weight/weight) is used to dissolve the polymer mixture.
  • biodegradable polymers e.g. a mixture of a linear polylactide-co-glycolide polymer and a branched polylactide-co-glycolide polymer, and Compound A pamoate as active ingredient
  • the microparticles have been prepared by a process for preparing
  • compositions can for instance be used in the manufacture of a medicament for the treatment of Acromegaly, GEP tumors, Cushing and Tumors such as e.g. Hepatocellular carcinoma, breast cancer.
  • Such compositions have an advantageous release profile for Compound A and in particular a reduced initial burst, as described in the present application.
  • Compound A (free base) may be present in an amount of from about 1 to about 35%, preferably from about 10 to about 35%, even more preferably from about 20% to about 30%, by weight of the microparticles dry weight.
  • the compound of the invention used to prepare the microparticles is in the form of an amorphous powder.
  • the particle size and/or the particle size distribution of the compound of the invention may influence the release profile of the drug from the microparticles.
  • the particles of the compound of the invention used to prepare the microparticles have a size of about 0.1 microns to about 15 microns, preferably less than about 5 microns, even more preferably less than about 3 microns.
  • the particle size distribution is preferably ⁇ 10 ⁇ 0.8 microns, i.e. 10% of the particles are smaller than 0.8 microns; ⁇ 50 ⁇ 3.0 microns i.e. 50% of the particles are smaller than 3.0 microns; or ⁇ 90 ⁇ 5.0 microns, i.e. 90% of the particles are smaller than 5.0 microns.
  • the polymer matrix of the microparticles comprises of one or more biodegradable polymers.
  • polymer is meant an homopolymer or a copolymer.
  • the polymer matrix of the microparticles consist of one or more biodegradable polymers.
  • the polymer matrix is designed to degrade sufficiently to be transported from the site of administration within one to 6 months after release of all or substantially all the active agent.
  • the preferred polymers of this invention are linear polyesters and branched chain polyesters (i.e. polyesters which have linear chains radiating from a polyol moiety, e.g. glucose).
  • the linear polyesters may be prepared from ⁇ -hydroxy carboxylic acids, e.g. lactic acid and/or glycolic acid, by condensation of the lactone dimers, see e.g. U.S. Pat. No. 3,773,919, the contents of which are incorporated herein by reference.
  • the preferred polyester chains in the linear or branched (star) polymers are copolymers of the ⁇ -carboxylic acid moieties, lactic acid and glycolic acid, or of the lactone dimers.
  • the molar ratio of lactide:glycolide of polylactide-co-glycolides in the linear or branched polyesters is preferably from about 75:25 to 25:75, e.g. 60:40 to 40:60, with from 55:45 to 45:55, e.g. 52:48 to 48:52 the most preferred. Particularly preferred is about 50:50.
  • Linear polyesters e.g. linear polylactide-co-glycolides (PLG), preferably used according to the invention have a weight average molecular weight (Mw) between about 10,000 and about 500,000 Da, e.g. between about 47,000 to about 63,000, e.g. about 50,000 Da.
  • Mw weight average molecular weight
  • Such polymers have a polydispersity M W /M n e.g. between 1.2 and 2.
  • Suitable examples include e.g. poly(D,L-lactide-co-glycolide), e.g.
  • Branched polyesters e.g. branched polylactide-co-glycolides, preferably used according to the invention may be prepared using polyhydroxy compounds e.g. polyol e.g. glucose or mannitol as the initiator. These esters of a polyol are known and described e.g. in GB 2,145,422 B, the contents of which are incorporated herein by reference.
  • the polyol contains at least 3 hydroxy groups and has a molecular weight of up to 20,000 Da, with at least 1, preferably at least 2, e.g. as a mean 3 of the hydroxy groups of the polyol being in the form of ester groups, which contain poly-lactide or co-poly-lactide chains. Typically 0.2% glucose is used to initiate polymerization.
  • the branched polyesters (Glu-PLG) have a central glucose moiety having rays of linear polylactide chains, e.g. they have a star shaped structure.
  • the branched polyesters having a central glucose moiety having rays of linear polylactide-co-glycolide chains may be prepared by reacting a polyol with a lactide and preferably also a glycolide at an elevated temperature in the presence of a catalyst, which makes a ring opening polymerization feasible.
  • the branched polyesters having a central glucose moiety having rays of linear polylactide-co-glycolide chains preferably have an weight average molecular weight M w in the range of from about 10,000 to 200,000, preferably 25,000 to 100,000, especially 35,000 to 60,000 or 47,000 to 63,000, e.g. about 50,000 Da, and a polydispersity e.g. of from 1.5 to 3.0, e.g. 1.7 to 2.5.
  • the intrinsic viscosities of star polymers of M w 35,000 or K w 60,000 are from 0.20 dl/g to 0.70 dl/g, such as e.g. 0.36 or 0.51 dl/g, respectively, in acetone or chloroform.
  • a star polymer having a M w 53,800 has a viscosity of 0.25 dl/g to 0.50 dl/g in acetone or chloroform such as e.g. 0.34 dl/g in acetone at room temperature.
  • the polymer matrix comprises a linear and a branched polylactide-co-glycolide. More preferably, the polymer matrix comprises a Resomer® RG and a star polylactide-co-glycolide polymer having a weight average molecular weight of between about 47,000 to about 63,000, e.g. about 50,000 Da.
  • the ratio of linear to branched polylactide-co-glycolide preferably is 50:50 to 25:75. More preferably the ratio is about 50:50.
  • the polymer matrix may be present in a total amount of about 40 to 99% by weight of the microparticles.
  • Suitable organic solvents for the polymers include halogenated hydrocarbons, e.g. methylene chloride, chloroform or hexafluoroisopropanol or ethyl acetate.
  • the preferred organic solvent is methylene chloride.
  • the concentration of the polymer mixture in methylene chloride is between 14.24% and 17.45% (weight polymer per weight polymer solution), preferably from 15.0% to 16.5%, even more preferred about 15.9% (weight/weight).
  • Suitable examples of a stabilizer for step (iib) include
  • polyvinyl alcohol or gelatine is used. Most preferred is polyvinyl alcohol, especially PVA 18-88.
  • concentration of the polymer mixture in methylene chloride of about 15.9% weight by weight.
  • the resulting microparticles may have a diameter from a few submicrons to a few millimeters; e.g. diameters of at most about 250 microns, e.g. 10 to 200 microns, preferably 10 to 130 microns, more preferably 10 to 90 microns, even more preferably 10 to 60 microns, are strived for, e.g. in order to facilitate passage through an injection needle.
  • a narrow particle size distribution is preferred.
  • the preferred particle size distribution is ⁇ 10 ⁇ 15 microns, ⁇ 50 ⁇ 40 microns and ⁇ 90 ⁇ 70 microns.
  • Unit doses may be produced which vary from about 75% to about 125%, e.g. about 85 to about 115%, e.g. from about 90 to about 110%, or from about 95 to about 105%, of the theoretical dose.
  • microparticles in dry state may e.g. be mixed, e.g. coated, with an anti-agglomerating agent, or e.g. covered by a layer of an anti-agglomerating agent e.g. in a prefilled syringe or vial.
  • Suitable anti-agglomerating agents include e.g. mannitol, glucose, dextrose, sucrose, sodium chloride, or water soluble polymers such as polyvinylpyrrolidone or polyethylene glycol, e.g. with the properties described above.
  • an anti-agglomerating agent is present in an amount of about 0.1 to about 10%, e.g. about 4% by weight of the microparticles.
  • the microparticles Prior to administration, the microparticles are suspended in a vehicle suitable for injection.
  • the present invention further provides a pharmaceutical composition comprising microparticles of the invention in a vehicle.
  • vehicle may optionally further contain: a) one or more wetting agents; and/or b) one or more tonicity agent; and/or c) one or more viscosity increasing agents.
  • the vehicle is water based, e.g. it may contain water, e.g deionized, and optionally a buffer to adjust the pH to 7-7.5, e.g. a phosphate buffer such as a mixture of Na 2 HPO 4 and KH 2 PO 4 , and one or more of agents a), b) and/or c) as indicated above.
  • a buffer to adjust the pH to 7-7.5, e.g. a phosphate buffer such as a mixture of Na 2 HPO 4 and KH 2 PO 4 , and one or more of agents a), b) and/or c) as indicated above.
  • the microparticles of the invention may not suspend and may float on the top of the aqueous phase.
  • the vehicle preferably comprises a wetting agent a).
  • the wetting agent is chosen to allow a quick and suitable suspendibility of the microparticles in the vehicle.
  • the microparticles are quickly wettened by the vehicle and quickly form a suspension therein.
  • Suitable wetting agents for suspending the microparticles of the invention in a water-based vehicle include non-ionic surfactants such as poloxamers, or polyoxyethylene-sorbitan-fatty acid esters, the characteristics of which have been described above.
  • a mixture of wetting agents may be used.
  • the wetting agent comprises Pluronic F68, Tween 20 and/or Tween 80.
  • the wetting agent or agents may be present in about 0.01 to about 1% by weight of the composition to be administered, preferably from 0.01 to 0.5% and may be present in about 0.01 to 5 mg/ml of the vehicle, e.g. about 2 mg/ml.
  • the vehicle further comprises a tonicity agent b) such as mannitol, sodium chloride, glucose, dextrose, sucrose, or glycerin.
  • a tonicity agent b) such as mannitol, sodium chloride, glucose, dextrose, sucrose, or glycerin.
  • the tonicity agent is mannitol.
  • the amount of tonicity agent is chosen to adjust the isotonicity of the composition to be administered.
  • a tonicity agent is contained in the microparticles, e.g. to reduce agglomeration as mentioned above, the amount of tonicity agent is to be understood as the sum of both.
  • mannitol preferably may be from about 1% to about 5% by weight of the composition to be administered, preferably about 4.5%.
  • the vehicle further comprises a viscosity increasing agent c).
  • Suitable viscosity increasing agents include carboxymethyl cellulose sodium (CMC-Na), sorbitol, polyvinyl-pyrrolidone, or aluminium monostearate.
  • CMC-Na with a low viscosity may conveniently be used. Embodiments may be as described above. Typically, a CMC-Na with a low molecular weight is used.
  • the viscosity may be of from about 1 to about 30 mPa s, e.g. from about 10 to about 15 mPa s when measured as a 1% (w/v) aqueous solution at 25° C. in a Brookfield LVT viscometer with a spindle 1 at 60 rpm, or a viscosity of 1 to 15 mPa*s for a solution of NaCMC 7LF (low molecular weight) as a 0.1 to 1% solution in water.
  • a polyvinylpyrrolidone having properties as described above may be used.
  • a viscosity increasing agent e.g. CMC-Na
  • CMC-Na may be present in an amount of from about 0.1 to about 2%, e.g. about 0.7% or about 1.75% of the vehicle (by volume), e.g. in a concentration of about 1 to about 30 mg/ml in the vehicle, e.g. about 7 mg/ml or about 17.5 mg/ml.
  • the present invention provides a kit comprising microparticles of the invention and a vehicle of the invention.
  • the kit may comprise microparticles comprising the exact amount of compound of the invention to be administered, e.g. as described below, and about 1 to about 5 ml, e.g. about 2 ml of the vehicle of the invention.
  • the dry microparticles may be filled into a container, e.g. a vial or a syringe, and sterilized e.g. using ⁇ -irradiation.
  • a container e.g. a vial or a syringe
  • the microparticles may be suspended in the container by adding a suitable vehicle, e.g. the vehicle described above.
  • the microparticles, optionally in admixture with an anti-agglomerating agent, a viscosity increasing agent and/or a tonicity agent, and the vehicle for suspension may be housed separately in a double chamber syringe.
  • a mixture of the microparticles with an anti-agglomerating agent and/or a viscosity increasing agent and/or a tonicity agent also forms part of the invention.
  • dry sterilized microparticles may be suspended in a suitable vehicle, e.g. the vehicle described above, and filled into a container, e.g. a vial or a syringe.
  • a suitable vehicle e.g. the vehicle described above
  • the solvent of the vehicle e.g. the water
  • the microparticles and solid components of the vehicle may be suspended in the container by adding a suitable vehicle, e,g, water, e.g.
  • the mixture of the microparticles, optionally the anti-agglomerating agent, and solid components of the vehicle and the vehicle for suspension e.g. water, may be housed separately in a double chamber syringe.
  • microparticles and the compositions of the invention are useful as the microparticles and the compositions of the invention.
  • the microparticles and the compositions of the invention are useful in the treatment of acromegaly and cancer, e.g. Cushing's Disease or Syndrome, carcinoids.
  • microparticles and the compositions of the invention may be tested in standard animal tests or clinical trials.
  • microparticles and the compositions of the invention are well-tolerated.
  • the compounds of the invention are released from the microparticles of the invention and from the compositions of the invention over a period of several weeks e.g. about 4 weeks to about 8 weeks, preferably about 4 weeks to about 6 weeks.
  • composition of the invention will of course vary, e.g. depending on the condition to be treated (for example the disease type or the nature of resistance), the drug used, the effect desired and the mode of administration.
  • Suitable monthly dosages for patients are thus in the order of about 0.3 mg to about 100 mg of Compound A.
  • the polymers are dissolved in an amount of methylene chloride as indicated in Table 1.
  • the polymer solution is then added to the Compound A pamoate.
  • the resulting suspension is treated with an Ultra-Turrax for 1 min.
  • the polymer/drug suspension and the PVA/phosphate solution are mixed at constant pump rates of 90 ml/min and 1800 ml/min at a mixing speed of 3300 upm, methylene chloride is evaporated under vacuum using a temperature program, which heats 2° C. per 20 min over 300 min. Subsequently, the microparticles are filtered off, washed with water (WBU) and dried under reduced pressure (0.1 mbar) at room temperature.
  • WBU water
  • Dried microparticles are filled in vials, evacuated and terminally sterilized. Terminal sterilization is performed by gamma-irradiation applying irradiation dose of 27.7 to 34.1 kGy.
  • CMC-Na, Mannitol and Pluronic F68 in an amount as given in Table 2 are dissolved in about 15 ml hot deionized water of a temperature of about 90° C. under strong stirring with a magnetic stirrer.
  • the resulting clear solution is cooled to 20° C. and filled up with deionized water to 20.0 ml.
  • Microparticles of example 1 and of Reference Example in an amount corresponding to 4 mg of Compound A per kg of the rabbit are suspended in 1 ml of the vehicle composition D.
  • the suspension is homogenized by shaking for about 30 seconds and injected into the left Musculus gastronemius of rabbits (Male Chinchilla bastard rabbits, about 7 months old), weighing about 3 kg before onset of the study, using an 19G needle.
  • Plasma samples (about 1 ml) are collected over 55 days. Plasma levels of Compound A are determined using an ELISA method. Mean concentration of Compound A after administration is given in Table 3. Mean AUC (0-55 d) is found to be 287 ng/ml d for example 1 and 227 ng/ml d for reference example.
  • the samples were weighted into polyester bags of 4 ⁇ 4 cm and tightly sealed.
  • the sample bags were placed into 50 ml Schott bottles and 50 ml of pre-warmed (37° C.) medium was added.
  • Medium was prepared by dissolving e.g. 2.98 g di-sodium hydrogen phosphate dihydrate, 8.0 g sodium chloride, 0.19 g potassium dihydrogen phosphate, 0.01 g benzalkonium chloride and 0.2 g tween 80 in 1000 ml of water and adjusting the pH with phosphoric acid 85% to 7.4
  • the burst can be measured as % Drug Content which is the percentage of drug released related to the before determined assay, i.e. if 100 mg MP contains 25 mg Compound A and 0.25 mg Compound A are released after 24 h this means the burst is 1%.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
US12/600,740 2007-05-24 2008-05-23 Extended-Release Composition Comprising a Somatostatin Derivative in Microparticles Abandoned US20100178344A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07108796.9 2007-05-24
EP07108796 2007-05-24
PCT/EP2008/056347 WO2008142153A1 (en) 2007-05-24 2008-05-23 An extended-release composition comprising a somatostatin derivative in microparticles

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/056347 A-371-Of-International WO2008142153A1 (en) 2007-05-24 2008-05-23 An extended-release composition comprising a somatostatin derivative in microparticles

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/743,385 Continuation US9351923B2 (en) 2007-05-24 2013-01-17 Extended-release composition comprising a somatostatin derivative in microparticles

Publications (1)

Publication Number Publication Date
US20100178344A1 true US20100178344A1 (en) 2010-07-15

Family

ID=38222465

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/600,740 Abandoned US20100178344A1 (en) 2007-05-24 2008-05-23 Extended-Release Composition Comprising a Somatostatin Derivative in Microparticles
US13/743,385 Active US9351923B2 (en) 2007-05-24 2013-01-17 Extended-release composition comprising a somatostatin derivative in microparticles

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/743,385 Active US9351923B2 (en) 2007-05-24 2013-01-17 Extended-release composition comprising a somatostatin derivative in microparticles

Country Status (42)

Country Link
US (2) US20100178344A1 (pl)
EP (2) EP2164473B1 (pl)
JP (1) JP5507447B2 (pl)
KR (2) KR20100017904A (pl)
CN (1) CN101677965B (pl)
AR (1) AR066677A1 (pl)
AU (1) AU2008252931B2 (pl)
BR (1) BRPI0811904A2 (pl)
CA (1) CA2683935C (pl)
CL (1) CL2008001509A1 (pl)
CO (1) CO6241097A2 (pl)
CR (1) CR11078A (pl)
CU (1) CU24028B1 (pl)
DK (1) DK2164473T3 (pl)
DO (1) DOP2009000262A (pl)
EA (1) EA018203B1 (pl)
EC (1) ECSP099793A (pl)
ES (1) ES2761227T3 (pl)
GE (1) GEP20125582B (pl)
GT (1) GT200900302A (pl)
HN (1) HN2009003296A (pl)
HU (1) HUE046490T2 (pl)
IL (1) IL201571B (pl)
MA (1) MA31445B1 (pl)
ME (1) ME00955B (pl)
MX (1) MX2009012536A (pl)
MY (1) MY148915A (pl)
NI (1) NI200900207A (pl)
NZ (1) NZ580589A (pl)
PA (1) PA8781501A1 (pl)
PE (1) PE20090387A1 (pl)
PL (1) PL2164473T3 (pl)
PT (1) PT2164473T (pl)
SI (1) SI2164473T1 (pl)
SM (1) SMP200900099B (pl)
SV (1) SV2009003421A (pl)
TN (1) TN2009000447A1 (pl)
TW (1) TWI412373B (pl)
UA (1) UA97396C2 (pl)
UY (1) UY31103A1 (pl)
WO (1) WO2008142153A1 (pl)
ZA (1) ZA200907168B (pl)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070122470A1 (en) * 2005-11-30 2007-05-31 Dick Johansson New Combination Dosage Form
US20150087655A1 (en) * 2012-04-23 2015-03-26 Otsuka Pharmaceutical Co., Ltd. Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
WO2018106442A1 (en) * 2016-12-05 2018-06-14 Hyalo Technologies, LLC Method of sterilization of microparticles
US11672843B2 (en) * 2012-05-25 2023-06-13 Camurus Ab Somatostatin receptor agonist formulations

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120156304A1 (en) * 2010-12-15 2012-06-21 Thomas Tice Branched polyol polyesters, blends, and pharmaceutical formulations comprising same
KR101539313B1 (ko) 2011-04-25 2015-07-24 산동 루예 파마슈티칼 컴파니 리미티드 리스페리돈의 서방성 미소구체 조성물
EP3339372A1 (en) * 2016-12-22 2018-06-27 Solvay SA Glycolic acid polymer composition
CN110870853B (zh) * 2018-08-29 2020-12-11 深圳翰宇药业股份有限公司 缓释帕瑞肽微球及其制备方法
BR112021009265A2 (pt) * 2018-12-04 2021-08-10 Vanda Pharmaceuticals Inc. métodos para preparar e administrar uma formulação de depósito injetável de iloperidona cristalina, e, formulação de depósito injetável de iloperidona cristalina

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050074492A1 (en) * 1996-04-23 2005-04-07 Kinerton Limited, An Irish Corporation Sustained release ionic conjugate
WO2005046645A1 (en) * 2003-11-14 2005-05-26 Novartis Ag Microparticles comprising somatostatin analogues

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CH656884A5 (de) 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
CA2316052C (en) * 1989-07-07 2008-09-02 David Bodmer Sustained release formulations of water soluble peptides
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
FI106926B (fi) * 1989-07-07 2001-05-15 Novartis Ag Menetelmä pitkäaikaisesti vapautuvan koostumuksen muodostamiseksi
AU5678398A (en) * 1997-01-29 1998-08-18 Takeda Chemical Industries Ltd. Sustained-release microspheres, their production and use
EP1240896A3 (en) 1998-07-23 2003-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Encapsulation of water soluble peptides
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
GB0326602D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
MXPA06005952A (es) * 2003-11-25 2006-07-06 Novartis Ag Biomarcadores para determinar la eficacia del tratamiento con analogos de somatostatina.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050074492A1 (en) * 1996-04-23 2005-04-07 Kinerton Limited, An Irish Corporation Sustained release ionic conjugate
US20060121120A1 (en) * 1996-04-23 2006-06-08 Biomeasure, Inc. Sustained release ionic conjugate
WO2005046645A1 (en) * 2003-11-14 2005-05-26 Novartis Ag Microparticles comprising somatostatin analogues

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070122470A1 (en) * 2005-11-30 2007-05-31 Dick Johansson New Combination Dosage Form
US20150087655A1 (en) * 2012-04-23 2015-03-26 Otsuka Pharmaceutical Co., Ltd. Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
US9499525B2 (en) * 2012-04-23 2016-11-22 Otsuka Pharmaceutical Co., Ltd. Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
US10407415B2 (en) 2012-04-23 2019-09-10 Otsuka Pharmaceutical Co., Ltd. Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
US11672843B2 (en) * 2012-05-25 2023-06-13 Camurus Ab Somatostatin receptor agonist formulations
WO2018106442A1 (en) * 2016-12-05 2018-06-14 Hyalo Technologies, LLC Method of sterilization of microparticles
US10821200B2 (en) 2016-12-05 2020-11-03 Hyalo Technologies, LLC Method of sterilization of microparticles

Also Published As

Publication number Publication date
AU2008252931B2 (en) 2011-09-01
PE20090387A1 (es) 2009-04-28
AU2008252931A1 (en) 2008-11-27
JP2010527971A (ja) 2010-08-19
DK2164473T3 (da) 2019-12-16
HUE046490T2 (hu) 2020-03-30
MY148915A (en) 2013-06-14
TW200906437A (en) 2009-02-16
ZA200907168B (en) 2010-07-28
UA97396C2 (ru) 2012-02-10
SMAP200900099A (it) 2010-01-19
SMP200900099B (it) 2010-11-12
KR101930588B1 (ko) 2018-12-18
CA2683935A1 (en) 2008-11-27
HN2009003296A (es) 2014-02-10
TN2009000447A1 (en) 2011-03-31
WO2008142153A1 (en) 2008-11-27
CN101677965B (zh) 2015-09-09
CU20090200A7 (es) 2011-09-21
CO6241097A2 (es) 2011-01-20
EA018203B1 (ru) 2013-06-28
PA8781501A1 (es) 2008-12-18
US9351923B2 (en) 2016-05-31
PL2164473T3 (pl) 2020-07-27
NI200900207A (es) 2010-09-07
ME00955B (me) 2012-06-20
TWI412373B (zh) 2013-10-21
EP2164473A1 (en) 2010-03-24
ECSP099793A (es) 2010-01-29
NZ580589A (en) 2011-12-22
CU24028B1 (es) 2014-10-02
UY31103A1 (es) 2009-01-05
IL201571B (en) 2018-11-29
JP5507447B2 (ja) 2014-05-28
MX2009012536A (es) 2009-12-03
ES2761227T3 (es) 2020-05-19
GT200900302A (es) 2011-07-01
EP2164473B1 (en) 2019-09-11
SV2009003421A (es) 2010-05-21
SI2164473T1 (sl) 2020-02-28
KR20100017904A (ko) 2010-02-16
CA2683935C (en) 2016-07-19
US20130129798A1 (en) 2013-05-23
BRPI0811904A2 (pt) 2014-11-18
PT2164473T (pt) 2019-12-11
CN101677965A (zh) 2010-03-24
CR11078A (es) 2009-12-04
GEP20125582B (en) 2012-07-25
CL2008001509A1 (es) 2009-05-08
AR066677A1 (es) 2009-09-02
DOP2009000262A (es) 2010-10-15
IL201571A0 (en) 2010-05-31
MA31445B1 (fr) 2010-06-01
EA200901523A1 (ru) 2010-04-30
EP3666263A1 (en) 2020-06-17
KR20160002937A (ko) 2016-01-08

Similar Documents

Publication Publication Date Title
US9351923B2 (en) Extended-release composition comprising a somatostatin derivative in microparticles
US8188037B2 (en) Microparticles comprising somatostatin analogues
AU2007263004A1 (en) Sustained release formulations of aromatase inhibitors

Legal Events

Date Code Title Description
AS Assignment

Owner name: NOVARTIS AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LAMBERT, OLIVIER;RIEMENSCHNITTER, MARC;VUCENOVIC, VITOMIR;SIGNING DATES FROM 20080408 TO 20080410;REEL/FRAME:023698/0216

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: RECORDATI AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS AG;REEL/FRAME:051945/0630

Effective date: 20190712